Danaher Corporation (DHR): FMR LLC now owns 5.6% of DHR as a passive investor 5.6%

5.6%

Stake · was 5.6%

39.2M

Shares owned

Stake as of

Sep 30, 2026

Filed

Nov 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 31, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On August 3, 2026, Danaher Corporation (the “Company” or “Danaher”) announced that, effective as of October 1, 2026 (the “Effective Date”), the Board of Directors of the Company (the “Board”) has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company (the “CEO”).”
2. Aug 7, 2026FDAFDA device clearance: Xpert Hemorrhagic Fever
3. Aug 7, 2026FDAFDA device clearance: Aperio iQC DX Software
4. Aug 7, 2026FDAFDA device clearance: Aperio GT 450 DX; Aperio GT 180 DX
5. Aug 12, 2026FDARecall: DxU 840m Iris, REF: C76947; DxU 850m Iris, REF: C49513
6. Aug 12, 2026FDARecall: IQ200 SPRINT, REF: 700-3322,700-3322RFB, 700-3325, 700-3326, B48997; IQ200 SELECT, REF: 700-3340, 700-3345, 700-3347, B48998, C10684; IQ200 ELITE, REF: 700-337…
7. Aug 18, 2026FDARecall: The ABL90 FLEX and ABL90 FLEX PLUS analyzers are intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a labo…
8. Aug 21, 2026Insider · 1 personInsiders: 3 sales (~$12.7M)
9. Aug 31, 2026CongressDisclosed sale of DHR — reported range $15,001 - $50,000
10. Sep 2, 2026FDARecall: DxC 500 AU Clinical Chemistry Analyzers: 1. AU w/out ISE, Part No. C63519 2. AU w/ISE, Part No. C63520
11. Sep 2, 2026FDARecall: DxC 500i Clinical Analyzer Modules: 1. DxC 500 AU Module w/ISE, DxC 500i, Part No. C63522 2. DxC 500 AU Module, DxC 500i, Part No. C63521 3. Access 2 Module, D…
12. Sep 2, 2026CongressDisclosed partial sale of DHR — reported range $1,001 - $15,000
13. Sep 21, 2026FDAFDA device clearance: Access NT-proBNP
14. Sep 21, 2026FDARecall: ROTOR ASSY-SW41, Reference Number 331362, when the rotors are installed in the following centrifuges: Optima XPN-100 (Model Numbers A99846 and A94469), Optima…
15. Sep 21, 2026FDARecall: ROTOR ASSY-SW40, Reference Number 331302, when the rotors are installed in the following centrifuges: Optima XPN-100 (Model Numbers A99846 and A94469), Optima…
16. Sep 25, 2026FDAFDA device clearance: Xpert Respiratory Panel

What came next

1. Oct 9, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 9, 2026, the Board of Directors (the “Board”) of Danaher Corporation (the “Company” or “Danaher”) increased the size of the Board to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg to the Board, in each case effective immediately.”
2. Oct 19, 2026FDAFDA device clearance: Access MeMed BV
3. Oct 20, 2026FDAFDA device clearance: Access BNP II
4. Oct 21, 2026Company filing · Form 8-K · ResultsReported its results
5. Oct 28, 2026Insider · 2 peopleInsiders: 4 sales (~$8.8M)
6. Oct 30, 2026FDAFDA device clearance: Xpert® Hemorrhagic Fever Panel
7. Nov 5, 20265% stakeFMR LLC reported a passive stake (13G) of 5.6%
8. Nov 9, 2026Insider · 2 peopleInsiders: 2 sales (~$4.6M)

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Danaher Corporation

For Danaher Corporation, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DHR page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Danaher Corporation

• SEC Form 144Nov 10, 2026
• SEC Form 4Nov 10, 2026
• SEC Form 4Nov 10, 2026
• SEC Form 144Nov 9, 2026
• SEC Form 144Nov 9, 2026
• SEC Form 144Nov 9, 2026

Everything OQRO holds on this company is on its DHR page.